Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Luis Miguel da Silva"'
Autor:
Layde Rosane Paim, Luis Miguel da Silva, Lígia M. Antunes-Correa, Vinicius Citelli Ribeiro, Roberto Schreiber, Eduarda O.Z. Minin, Larissa C.M. Bueno, Elisangela C.P. Lopes, Renan Yamaguti, Andréa Coy-Canguçu, Sergio San Juan Dertkigil, Andrei Sposito, Jose Roberto Matos-Souza, Thiago Quinaglia, Tomas G. Neilan, Licio A. Velloso, Wilson Nadruz, Michael Jerosch-Herold, Otavio R. Coelho-Filho
Publikováno v:
Heliyon, Vol 10, Iss 6, Pp e27206- (2024)
Background and aims: Cardiomyocyte hypertrophy and interstitial fibrosis are key components of myocardial remodeling in Heart Failure (HF) with preserved (HFpEF) or reduced ejection fraction (HFrEF). MicroRNAs (miRNAs) are non-coding, evolutionarily
Externí odkaz:
https://doaj.org/article/eaa9d3f818ab46b9aaa81b7cf96f7904
Autor:
Luis Miguel Da Silva, Andréa Coy-Canguçu, Layde R Paim, Adriana Aparecida Bau, Camila Nicolela Geraldo Martins, Lígia Antunes-Correa, Celso Dario Ramos, Michael Jerosch-Herold, PhD, Otávio rizzi Coelho-Filho
Publikováno v:
Journal of Cardiovascular Magnetic Resonance, Vol 26, Iss , Pp 100732- (2024)
Externí odkaz:
https://doaj.org/article/d42b2816bc6c4e84ab14e16d06992531
Autor:
Cristiane Nardi Gemme, Thiago Quinaglia A. C. Silva, Luiz C. Martins, Luis Miguel da Silva, Layde Rosane Paim, Andrei Sposito, Wilson Nadruz, Fabio Fernandes, Sergio San Juan Dertkigil, Jamiro da Silva Wanderley, Eros A. de Almeida, Konradin Metze, Tomas G. Neilan, Michael Jerosch-Herold, Otávio R. Coelho-Filho
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundChronic Chagas cardiomyopathy (CCC) constitutes the most life-threatening consequence of the Trypanosoma cruzi infection. Our goal was to test in CCC the associations of the myocardial tissue phenotype with cardiac dysfunction, and heart fa
Externí odkaz:
https://doaj.org/article/0dcc29b46f9f4f3bb2ece445baad8af1
Autor:
Caio Rebouças Fonseca Cafezeiro, Otavio R. Coelho-Filho, Edmundo Arteaga, Charles Mady, Luis Miguel da Silva
Publikováno v:
Revista da Sociedade de Cardiologia do Estado de São Paulo. 31:181-186
A miocardiopatia hipertrófica (MCH) é diagnosticada quando se evidencia em métodos de imagem espessura máxima diastólica ≥ 15 mm em qualquer segmento miocárdico no ventrículo esquerdo (VE), ou ao menos 13 mm quando a doença está presente n
Autor:
Gabriel da Silva Ferreira, Otavio R. Coelho-Filho, Rodrigo Modolo, Ligia M. Antunes-Correa, Wilson Nadruz, Vinicius Citelli Ribeiro, Pedro Vellosa Schwartzmann, Luis Miguel da Silva, Luis Sergio F. Carvalho, Fernando Bianchini Cardoso, José Roberto Matos Souza, Layde R. Paim, Andrei C. Sposito, Camila Toledo
Publikováno v:
ESC Heart Failure, Vol 8, Iss 3, Pp 2133-2143 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Despite of recent advances in the pharmacological treatment, heart failure (HF) maintains significant morbidity and mortality rates. While serum potassium disorders are common and associated with adverse outcomes, the exact recommended potassium
Autor:
Camila Nicolela Geraldo Martins, Adriana Aparecida Bau, Otavio Coelho Filho, Luis Miguel da Silva
Publikováno v:
ABC: Heart Failure & Cardiomyopathy. 1:33-43
Resumo Os inibidores dos cotransportadores sodio-glicose 2 (SGLT2) foram introduzidos originalmente para o tratamento de diabetes melito (DM2) em 2013, entre eles canaglifozina, dapaglifozina e empaglifozina. Os estudos de seguranca cardiovascular de
Autor:
Otavio Berwanger, Thiago Quinaglia A. C. Silva, Roberto Schreiber, Layde R. Paim, Camilla Toledo, Otavio R. Coelho-Filho, Wilson Nadruz, Andrei C. Sposito, Celso Dario Ramos, Michael Jerosch-Herold, Tomas G. Neilan, Licio A. Velloso, Luis Miguel da Silva, José R. Matos-Souza, Sergio Dertkigil, Ligia M. Antunes-Correa, Vinicius Citelli Ribeiro, Fernando Bianchini Cardoso
Publikováno v:
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease, Vol 10 (2019)
Therapeutic Advances in Chronic Disease, Vol 10 (2019)
Background:Studies have shown significant benefits of exercise therapy in heart failure (HF) with a reduced ejection fraction (HFrEF) and HF with a preserved ejection fraction (HFpEF). The mechanisms responsible for the beneficial effect of exercise